Q2 2026 saw 13% organic revenue growth, margin expansion, and strong performance in Proteins and Analytics. Full-year guidance was raised for revenue and EPS, with robust order momentum and a strategic BioLife acquisition expected to accelerate growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.